A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens

• Main Authors: Homkham N., Cressey T., Ingsrisawang L., Bouazza N., Ngampiyaskul C., Hongsiriwon S., Srirojana S., Kanjanavanit S., Bhakeecheep S., Coeur S., Salvadori N., Treluyer J., Jourdain G., Urien S.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84959423363&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42663
• Institution: Chiang Mai University

© 2016, The American College of Clinical Pharmacology Efavirenz use is associated with changes in cholesterol concentrations, but it is unclear whether this effect is related to drug concentrations. Using efavirenz and cholesterol plasma concentrations measured in 87 antiretroviral-naive children in...